Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma

被引：17
|
作者：
Gautschi, Oliver [1 ]
Menon, Roopika [2 ]
Bertrand, Miriam [2 ]
Murer, Christian [1 ]
Diebold, Joachim [1 ]
机构：
[1] Cantonal Hosp Lucerne, Luzern, Switzerland
[2] NEO New Oncol GmbH, Cologne, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期
关键词：
D O I：
10.1016/j.jtho.2019.07.027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E13 / E15
页数：4
相关论文
共 50 条
  • [41] Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
    Piper-Vallillo, Andrew J.
    Sequist, Lecia, V
    Piotrowska, Zofia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2926 - +
  • [42] Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
    Bertino, Erin M.
    Gentzler, Ryan D.
    Clifford, Sarah
    Kolesar, Jill
    Muzikansky, Alona
    Haura, Eric B.
    Piotrowska, Zofia
    Camidge, D. Ross
    Stinchcombe, Thomas E.
    Hann, Christine
    Malhotra, Jyoti
    Villaruz, Liza C.
    Paweletz, Cloud P.
    Lau, Christie L.
    Sholl, Lynette
    Takebe, Naoko
    Moscow, Jeffrey A.
    Shapiro, Geoffrey, I
    Janne, Pasi A.
    Oxnard, Geoffrey R.
    CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1604 - 1611
  • [43] The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma
    Zhou, Wensheng
    Liu, Zhichao
    Wang, Yanan
    Zhang, Yanwei
    Qian, Fangfei
    Lu, Jun
    Wang, Huimin
    Gu, Ping
    Hu, Minjuan
    Chen, Ya
    Yang, Zhengyu
    Zhao, Ruiying
    Lou, Yuqing
    Han, Baohui
    Zhang, Wei
    CANCER MEDICINE, 2022, 11 (05): : 1299 - 1309
  • [44] Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages
    Wang, Don-Hong
    Lee, Hyun-Sung
    Yoon, David
    Berry, Gerald
    Wheeler, Thomas M.
    Sugarbaker, David J.
    Kheradmand, Farrah
    Engleman, Edgar
    Burt, Bryan M.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 778 - 788
  • [45] Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma
    Rosell, Rafael
    Karachaliou, Niki
    LANCET RESPIRATORY MEDICINE, 2018, 6 (09): : 649 - 651
  • [46] Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
    Shen, C-I.
    Chiu, C-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Acquired ALK Rearrangement in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR TKIs
    Wang, Q.
    Chen, R.
    Kang, J.
    Chen, H.
    Wang, B.
    Wang, Z.
    Zhou, Q.
    Wu, Y.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S569 - S570
  • [48] Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib
    Kang, Jin
    Chen, Hua-Jun
    Wang, Zheng
    Liu, Jing
    Li, Bing
    Zhang, Tengfei
    Yang, Zhenfan
    Wu, Yi-Long
    Yang, Jin-Ji
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : E49 - E53
  • [49] A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy
    Inomata, Minehiko
    Furukawa, Daisuke
    Takata, Naoki
    Tokui, Kotaro
    Okazawa, Seisuke
    Imanishi, Shingo
    Nomura, Satoshi
    IN VIVO, 2025, 39 (02): : 1207 - 1210
  • [50] OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC
    不详
    CANCER DISCOVERY, 2017, 7 (10) : 1061 - 1061
12345